Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Non-alcoholic Steatohepatitis (NASH) Cirrhosis: Twenty-Two Years Data from the Scientific Registry of Transplant Recipients (SRTR)

被引:0
作者
Younossi, Zobair M. [1 ,4 ]
Stepanova, Maria [2 ]
Locklear, Cameron T. [1 ]
Jacobson, Ira [3 ]
Mishra, Alita [1 ]
Trimble, Gregory [1 ]
Erario, Madeline [1 ]
Venkatesan, Chapy [1 ]
Younossi, Issah [2 ]
Arsalla, Aimal [4 ]
Keo, Wisna'odom [4 ]
Goodman, Zachary D. [1 ]
机构
[1] Inova Fairfax Hosp, Dept Med, Ctr Liver Dis, Falls Church, VA USA
[2] Ctr Outcomes Res Liver Dis, Washington Dc, DC USA
[3] Med Mt Sinai Beth Israel, New York, NY USA
[4] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
1682
引用
收藏
页码:899A / 900A
页数:2
相关论文
共 31 条
[31]   REAL-WORLD EFFECTIVENESS OF HEPATITIS C VIRUS (HCV) TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAA) IN POPULATIONS WITH FATTY LIVER/NON-ALCOHOLIC STEATOHEPATITIS (FL/NASH), DECOMPENSATED CIRRHOSIS (DCC), HEPATOCELLULAR CARCINOMA (HCC), AND/OR POST LIVER TRANSPLANT (PTX) [J].
Younossi, Z. ;
Bacon, B. ;
Curry, M. ;
Flamm, S. L. ;
Frick, A. ;
Milligan, S. ;
Radtchenko, J. ;
Tsai, N. ;
Afdhal, N. .
VALUE IN HEALTH, 2020, 23 :S168-S168